Mazdutide is a once-weekly injectable peptide that activates both the GLP-1 receptor and the glucagon receptor. Developed by Innovent Biologics under license from Eli Lilly, it was approved in China in 2025 for chronic weight management and, separately, for glycemic control in type 2 diabetes. It has not been approved anywhere else, and Eli Lilly, which holds rights outside China, has only reached phase 2 in the United States.
Ask about Mazdutide
Research snapshot
| Category | Current information | ||||
|---|---|---|---|---|---|
| Peptide category | Dual GLP-1 / glucagon (GCG) receptor agonist (oxyntomodulin analogue) | ||||
| Primary research interest | Chronic weight management; glycemic control in type 2 diabetes | ||||
| Highest available evidence | Tier 1 – multiple published/peer-reviewed phase 3 trials supporting Chinese regulatory approval | ||||
| Human research available | Yes – phase 3 programme of several thousand participants, entirely in China | ||||
| Development status | Approved in China (Innovent Biologics, under license from Eli Lilly); phase 2 only in the US | ||||
| Regulatory status | NMPA-approved (China) for weight management (June 2025) and type 2 diabetes (September 2025); not approved in the US, EU, or UK | ||||
| DREAMS-3, type 2 diabetes with obesity (head-to-head vs. semaglutide 1 mg) | Subcutaneous | 6 mg | Once weekly | 32 weeks | Company-reported phase 3 topline (design paper published, results not peer-reviewed) |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | Mazdutide |
| Alternative names | IBI362, LY3305677 (code names), mazdutide acetate |
| Peptide sequence | 39 amino acid oxyntomodulin-analogue peptide with a C-18 fatty diacid side chain for albumin binding |
| Amino-acid length | 39 residues |
| Molecular formula | C210H322N46O67 |
| Molecular weight | 4563.14 g/mol |
| CAS Registry Number | 2259884-03-0 |
| PubChem CID | 167312357 |
| Chemical modifications | C-18 fatty diacid conjugation via linker, promoting albumin binding for once-weekly dosing |
| Peptide class | Oxyntomodulin analogue, dual GLP-1/glucagon receptor agonist |
| Primary biological target | GLP-1 receptor and glucagon receptor (balanced activation) |
| Developer or originator | Innovent Biologics, co-developed with Eli Lilly |
| Development status | Approved in China; phase 2 in the US |
What it is
Mazdutide (development codes IBI362 and LY3305677) is a 39 amino acid synthetic peptide modeled on oxyntomodulin, a natural gut hormone that activates both the GLP-1 receptor and the glucagon receptor. A fatty acid side chain lets it bind albumin in the blood, extending its action to support once-weekly dosing. Innovent Biologics and Eli Lilly co-developed it, with Innovent leading commercialization in China. China’s National Medical Products Administration approved it in June 2025 for chronic weight management and in September 2025 for glycemic control in type 2 diabetes, the first approvals anywhere for a dual GCG/GLP-1 receptor agonist. It is not approved in the United States, the European Union, or any other market as of September 2026; Eli Lilly is developing it separately outside China and has completed only a phase 2 trial there.
How does it work?
Plain-English explanation
Mazdutide mimics two hormones at once. Like semaglutide and tirzepatide, it activates the GLP-1 receptor, which slows stomach emptying, reduces appetite, and helps the pancreas release insulin when blood sugar is high. It also activates the glucagon receptor, which increases the amount of energy the body burns at rest. The idea, shared with survodutide and pemvidutide, is that combining appetite reduction with a modest metabolic boost produces more weight loss than appetite reduction alone.
Technical explanation
Mazdutide is an oxyntomodulin analogue engineered for balanced activity at the human GLP-1 and glucagon receptors, in contrast to tirzepatide, which is GLP-1/GIP, and retatrutide, which adds a third receptor. A C-18 diacid fatty chain conjugated through a linker promotes albumin binding, giving it a half-life compatible with once-weekly subcutaneous dosing. Unlike liraglutide or semaglutide, it is not a modified GLP-1 molecule; it is built on the oxyntomodulin backbone, which is the structural reason it carries native glucagon-receptor activity rather than none at all.
Potential benefits and research applications
Weight loss in people with obesity or overweight
What is being investigated: whether combining GLP-1 and glucagon receptor activation produces more weight loss than GLP-1 activation alone. How the effect might occur: appetite suppression from the GLP-1 arm plus higher energy expenditure from the glucagon arm. Evidence: in GLORY-1, NEJM 2025 (610 Chinese adults, BMI 28 or higher, or 24 to 28 with a weight-related condition), the average change from starting weight at week 48 was -11.00 percent on 4 mg, -14.01 percent on 6 mg and +0.30 percent on placebo, counting everyone randomised whether or not they stayed on treatment. Sponsor communications cite higher figures (12.05 and 14.84 percent) that appear to come from a different, on-treatment style of analysis; the paper abstract gives the first set. In GLORY-2, JAMA 2026 (461 adults with BMI 30 or higher analysed, 60 weeks, 9 mg), the average change was -16.65 percent versus -1.50 percent on placebo, a gap of 15.15 points, and 84.3 percent lost at least 5 percent of body weight versus 33.1 percent on placebo. The sponsor’s earlier announcement cited 18.55 percent overall; the JAMA abstract does not say which analysis that figure came from. Strength: has been shown in two peer-reviewed phase 3 trials. Limitation: both enrolled only Chinese adults (GLORY-2 participants averaged about 34 years old and 64 percent were women), so how the results carry to other populations has not been directly tested.
Glycemic control in type 2 diabetes
What is being investigated: HbA1c reduction and weight loss in adults with type 2 diabetes, alone or added to other diabetes drugs. How the effect might occur: the GLP-1 arm’s insulin-secretion and appetite effects, standard for the class. Evidence: this is the basis of the September 2025 NMPA approval for glycemic control. In DREAMS-2, Nature 2025 (731 adults, 28 weeks), both mazdutide doses beat dulaglutide 1.5 mg: HbA1c was lower by 0.24 points on 4 mg and 0.30 points on 6 mg, and body weight was lower by 3.78 and 5.76 percent. A second phase 3 trial against placebo was published alongside it in Nature. In DREAMS-3, an open-label head-to-head of mazdutide 6 mg against semaglutide 1 mg in 349 adults with type 2 diabetes and obesity (DREAMS-3 design paper), trade press reporting the sponsor’s topline results gives HbA1c changes of -2.03 versus -1.84 percent and weight changes of about -10.3 versus -6 percent at 32 weeks; those results had not appeared in a peer-reviewed paper when this was checked. Strength: has been shown in multiple peer-reviewed phase 3 trials leading to formal regulatory approval in China. Limitation: Chinese participants only, short comparator trials, and semaglutide 1 mg is not the top semaglutide dose.
Liver fat, blood pressure, and lipid improvements (as a byproduct of weight loss)
What is being investigated: reductions in liver fat content, blood pressure, triglycerides, LDL cholesterol, and uric acid alongside weight loss. How the effect might occur: largely secondary to substantial weight reduction, a pattern shared across the GLP-1/glucagon and GLP-1/GIP drug class. Evidence: in the GLORY-1 and GLORY-2 trials, participants with elevated baseline liver fat saw reductions of roughly 63 to 74 percent by MRI, alongside improvements in waist circumference, systolic blood pressure, triglycerides, LDL cholesterol, and serum uric acid. Strength: has been shown in phase 3 imaging and laboratory substudies. Limitation: like the retatrutide and semaglutide liver findings, these are imaging and biomarker changes, not liver biopsy-confirmed resolution of steatohepatitis, and no dedicated liver-outcome trial for mazdutide has been published.
What the numbers mean, next to tirzepatide and semaglutide
Every trial below reports the same basic measure: the average percent change in body weight from the starting weight. Minus 14 percent means the average person ended up 14 percent lighter, which is about 14 kg (31 lb) on 100 kg (220 lb). It is an average, so individual results run well above and below it. The placebo column matters because people on placebo also lose or gain a little with the diet and activity advice every trial includes. The gap between the two is the part credited to the drug.
| Drug and top dose | Trial and population | Length | Weight change on drug | Weight change on placebo | Gap vs placebo (calculated) |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg weekly | STEP 1, adults with obesity, no diabetes | 68 weeks | -14.9% | -2.4% | -12.5 points |
| Tirzepatide 15 mg weekly | SURMOUNT-1, adults with obesity, no diabetes | 72 weeks | -20.9% | -3.1% | -17.8 points |
| Mazdutide 6 mg weekly | GLORY-1, Chinese adults with obesity or overweight | 48 weeks | -14.01% | +0.30% | -14.3 points |
| Mazdutide 4 mg weekly | GLORY-1, Chinese adults with obesity or overweight | 48 weeks | -11.00% | +0.30% | -11.3 points |
| Mazdutide 9 mg weekly | GLORY-2, Chinese adults with BMI 30 or higher | 60 weeks | -16.65% | -1.50% | -15.15 points (as reported) |
All five rows use the same style of analysis, which counts everyone who was randomised whether or not they stayed on treatment, so they are the conservative versions of each trial’s result. Gaps are simple subtraction done here except where marked as reported.
Why this is not a fair head-to-head. These are separate trials with different lengths (48, 60, 68 and 72 weeks), and weight keeps falling with time on treatment. The mazdutide trials enrolled Chinese adults, and GLORY-1 let people in at a lower BMI (28 or higher) than STEP 1 and SURMOUNT-1 (30 or higher, or 27 with a weight-related condition). Dose escalation rules also differ. No trial has compared mazdutide with tirzepatide.
The one direct comparison with semaglutide is in type 2 diabetes. In DREAMS-3 (open label, 349 adults, mazdutide 6 mg versus semaglutide 1 mg, 32 weeks) trade press reporting the company’s topline results gives average weight change of about -10.3 percent versus -6 percent. That has not appeared in a peer-reviewed paper, and semaglutide 1 mg is not the highest semaglutide dose. In the peer-reviewed DREAMS-2, mazdutide beat dulaglutide 1.5 mg on weight by 3.78 points (4 mg) and 5.76 points (6 mg) at 28 weeks.
A fair reading. On the numbers so far, mazdutide at its higher doses lands in the same neighborhood as semaglutide 2.4 mg and below tirzepatide 15 mg, but in a shorter, different population. Whether it does better or worse than either in a matched trial is not known. This says nothing about which drug suits any individual, and it covers weight only. Side effects are covered further down the page.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Every dose of mazdutide with published human data comes from company-sponsored, mostly peer-reviewed phase 3 trials (the DREAMS-3 topline is company-reported) conducted in China, all using once-weekly subcutaneous injection with a titration period before reaching a fixed maintenance dose. No independent, non-company dosing data exist, and no dosing outside these approved indications has been studied in a controlled trial.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| GLORY-1, obesity/overweight (China, approved) | Subcutaneous | 4 mg or 6 mg | Once weekly, titrated | 48 weeks | Published human clinical trial (NEJM) |
| GLORY-2, obesity with BMI 30 or higher (China, Phase 3) | Subcutaneous | 9 mg, two-step titration | Once weekly | 60 weeks | Published human clinical trial (JAMA 2026) |
| DREAMS-2, type 2 diabetes (China, approved) | Subcutaneous | 4 mg or 6 mg | Once weekly | 28 weeks | Published human clinical trial (Nature 2025, head-to-head vs. dulaglutide) |
All published dosing data come from company-sponsored trials conducted exclusively in Chinese adults. No independent academic trial, and no trial in a non-Chinese population, has been identified.
Amounts studied in human research
GLORY-1 (NEJM), the pivotal obesity and overweight trial, randomised 610 adults with obesity (BMI 28 or higher) or overweight (BMI 24-28) with at least one weight-related comorbidity to mazdutide 4 mg once weekly, 6 mg once weekly, or placebo, for 48 weeks, reaching mean weight changes of -11.00 and -14.01 percent respectively against +0.30 percent on placebo, counting all randomised participants.
A second phase 3 trial, GLORY-2, JAMA 2026, randomised 462 adults with BMI 30 or higher (about 16 percent with type 2 diabetes) 2:1 to mazdutide 9 mg once weekly or placebo for 60 weeks, with a two-step dose titration. The analysed group (461 people) averaged -16.65 percent versus -1.50 percent on placebo. Sponsor communications earlier reported 18.55 percent overall and 20.08 percent in people without diabetes; those higher figures were not located in the published abstract.
DREAMS-2 (DREAMS-2, Nature 2025), a head-to-head phase 3 trial in 731 adults with type 2 diabetes, compared mazdutide 4 mg and 6 mg once weekly with dulaglutide 1.5 mg once weekly over 28 weeks. Both mazdutide doses were superior on HbA1c (differences of -0.24 and -0.30 points) and on body weight (differences of -3.78 and -5.76 percent).
Two further phase 3 trials in type 2 diabetes, comparing mazdutide against placebo, were published together in Nature; exact per-arm dose and outcome figures from those two papers were not independently retrieved for this entry and are not reproduced here to avoid restating unverified numbers.
Practitioner and community-reported protocols
Not consistently reported. Because mazdutide is approved and sold only in China and has not reached the compounding or grey-market research-chemical channels common to semaglutide, tirzepatide, or retatrutide, this site did not identify an established community-reported dosing pattern for mazdutide outside its labeled use as of September 2026.
Side effects, risks, and limitations
Across the phase 3 obesity trials, the most frequently reported adverse events were gastrointestinal. In GLORY-2 at 9 mg, vomiting was reported by 53.1 percent of participants (1.3 percent on placebo), nausea by 46.9 percent (3.2 percent) and diarrhea by 39.4 percent (6.5 percent), mostly mild to moderate. Discontinuation for adverse events was 2.9 percent on mazdutide versus none on placebo in that trial, and 0.5 to 1.5 percent across the mazdutide arms of GLORY-1. Heart rate rose modestly (about 2.6 beats per minute) in the GLORY-1 mazdutide arms, without a reported cardiovascular safety signal. A BMJ Medicine network meta-analysis (2026) of trials in adults without diabetes found low-certainty evidence that mazdutide was better tolerated than several other next-generation incretin drugs, with wide uncertainty. As with every drug in this class, long-term cardiovascular and cancer outcome data are limited, and mazdutide has not been tested for as long, in as many people, or in as many countries as semaglutide or liraglutide.
Regulatory and developmental status
Mazdutide is approved by China’s NMPA for two indications: chronic weight management (June 2025, for adults who are overweight or obese with at least one weight-related comorbidity) and glycemic control in type 2 diabetes (September 2025, as monotherapy or combined with metformin, sulfonylureas, or SGLT2 inhibitors). It is not approved in the United States, the European Union, the United Kingdom, or any other jurisdiction identified for this entry. Eli Lilly, which holds development and commercialization rights outside China, has reported only a phase 2 trial in the United States; no phase 3 programme or regulatory filing outside China had been confirmed as of September 2026.
A dated list of what is expected next for mazdutide, with the source for each date, is on its card on the Weight Loss Atlas pipeline tracker.
Frequently asked questions
What is mazdutide?
A once-weekly injectable peptide that activates both the GLP-1 and glucagon receptors, approved in China for chronic weight management and for type 2 diabetes. It is not approved in the United States or Europe.
How does it work?
It combines a GLP-1 receptor effect, which reduces appetite and slows digestion, with a glucagon receptor effect, which modestly raises resting energy expenditure, an approach it shares with survodutide and pemvidutide.
What dosage has been studied?
Phase 3 trials used 4 mg, 6 mg and 9 mg once weekly by subcutaneous injection, each reached through a titration period before the trial’s fixed maintenance dose.
What dosage commonly circulates online?
Not consistently reported. Mazdutide has not shown up in the same grey-market research-chemical channels as semaglutide, tirzepatide, or retatrutide, likely because its approved supply chain runs through China rather than through peptide vendors sourcing from Western clinical trial leftovers or synthesis labs.
How much weight loss has been shown?
Average weight change of -11.00 percent at 4 mg and -14.01 percent at 6 mg over 48 weeks in GLORY-1, and -16.65 percent at 9 mg over 60 weeks in GLORY-2, against about +0.3 to -1.5 percent on placebo. Sponsor communications cite somewhat higher figures from other analyses.
Has it been studied in humans?
Yes, in a phase 3 programme of several thousand participants in China spanning obesity, overweight, and type 2 diabetes, leading to two separate NMPA approvals.
Is it approved in the United States?
No. It is approved only in China. Eli Lilly holds rights outside China and has reported only a phase 2 trial in the United States as of September 2026.
What side effects have been reported?
Mostly gastrointestinal: nausea, diarrhea, and vomiting, generally mild to moderate. A modest increase in heart rate was also reported, without an identified cardiovascular safety signal in the trials conducted so far.
What remains unknown?
Long-term cardiovascular and cancer outcomes, safety and efficacy outside the Chinese population studied in its pivotal trials, and whether or when it will be reviewed by the FDA or EMA.
Bottom line
Mazdutide is a dual GLP-1/glucagon receptor agonist with a genuine, publicly documented phase 3 record and two real regulatory approvals in China, one for weight management and one for type 2 diabetes. Its weight-loss figures (roughly 11 to 17 percent depending on dose and trial) are credible and now come from peer-reviewed trials, but the entire evidence base to date comes from Chinese trial populations, and it remains unapproved and comparatively under-studied everywhere else, including the United States. It has not shown up in the community and grey-market research-chemical circulation seen with semaglutide, tirzepatide, or retatrutide.
Related entries: eloralintide, Lilly’s investigational amylin receptor agonist; orforglipron, an oral non-peptide GLP-1 agonist.
Sources
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025. Human phase 3, n=610, 48 weeks. Source for the 4 mg and 6 mg weight loss, waist circumference, and liver fat results. DOI 10.1056/NEJMoa2411528
- Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2025. Human phase 3. One of two back-to-back phase 3 diabetes papers; per-arm numeric results were not independently extracted for this entry. DOI 10.1038/s41586-025-10026-w
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2025. Human phase 3, companion paper to the placebo-controlled trial above. DOI 10.1038/s41586-025-10031-z
- Innovent Biologics. Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints. Company press release, not yet an independently reviewed publication as of this entry's writing. PRNewswire, 2025
- Innovent Biologics. Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints. Company press release; numeric HbA1c and weight results were not disclosed in this release. PRNewswire, 2024
- Innovent Biologics. Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management. June 2025. PRNewswire, June 2025
- Innovent Biologics. Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes. September 2025. PRNewswire, September 2025
- National Center for Biotechnology Information. PubChem Compound Summary for CID 167312357, Mazdutide. Source for molecular formula and CAS number. PubChem CID 167312357
- Gao L, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026;336(5):377-388. Human phase 3, 461 analysed, 60 weeks. Source for the -16.65 vs -1.50 percent result and GI adverse event rates. DOI 10.1001/jama.2026.8142
- Chen D, et al. Comparative efficacy and safety of GLP-1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. BMJ Med. 2026;5(1):e003026. Source for the low-certainty tolerability comparison. DOI 10.1136/bmjmed-2026-003026
- Luo Y, et al. Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3. Contemp Clin Trials. 2025;160:108150. Trial design only; results were not published in a peer-reviewed paper when checked. DOI 10.1016/j.cct.2025.108150
Compare Mazdutide with related compounds
Research area: Metabolic and incretin.